Immune activation, HIV persistence, and the cure

Topics in Antiviral Medicine

Volumn 21, Issue 4, 2013, Pages 128-132

  Douek, Daniel C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Gut; HIV; Immune activation; Lymphoid tissue; Microbial translocation; Persistence; Raltegravir intensification; Reservoir

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBROTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CENICRIVIROC; FATTY ACID BINDING PROTEIN 2; GROWTH HORMONE; INTERLEUKIN 7; MARAVIROC; RALTEGRAVIR; RIFAXIMIN; SEVELAMER; TUMOR NECROSIS FACTOR INHIBITOR; VITAMIN D; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADAPTIVE IMMUNITY; ARTICLE; BLOOD CLOTTING DISORDER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLOSTRUM; CYTOMEGALOVIRUS INFECTION; ENTEROPATHY; EPITHELIUM CELL; EPSTEIN BARR VIRUS INFECTION; GASTROINTESTINAL TRACT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTESTINE FLORA; MEMBRANE PERMEABILITY; PERSISTENT VIRUS INFECTION; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; ZOONOSIS; BACTERIAL TRANSLOCATION; CELLULAR IMMUNITY; DRUG EFFECTS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS LATENCY;

ANTI-HIV AGENTS; BACTERIAL TRANSLOCATION; GASTROINTESTINAL TRACT; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; PYRROLIDINONES; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84887160135     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126-133.
2. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187(10): 1534-1543.
3. Hunt P, Rodriguez B, Shive C, et al. Gut epithelial barrier dysfunction, inflammation, and coagulation predict higher mortality during treated HIV/AIDS [Abstract 278]. 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2012; Seattle, Washington.
4. Llibre JM, Buzon MJ, Massanella M, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther. 2012;17(2):355-364.
5. Vallejo A, Gutierrez C, Hernandez-Novoa B, et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS. 2012;26(15):1885-1894.
6. Ghandi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Clin Trials. 2010;7(8):pii:e1000321.
7. Sheth PM, Yi TJ, Kovacs C, et al. Mucosal correlates of isolated HIV semen shedding during effective antiretroviral therapy. Mucosal Immunol. 2012;5(3):248-257.
8. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24(16):2451-2460.
9. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211.
10. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011;203(7):960-968.
11. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/ Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692-698.
12. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. 2003;3(4):331-341.
13. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008;1(1): 23-30.
14. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013;254(1):326-342.
15. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55(1):126-136.
16. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12(8):607-614.
17. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10(9):655-666.